XFOR$3.350.30%-0.010
After Hours: 3.350.00 0.00%
X 4 Pharmaceuticals Inc (XFOR)
Date: 2026-10-30 16:00O: 3.33H: 3.41L: 3.19C: 3.35Vol: 706.2k
X 4 Pharmaceuticals Inc stock is traded at $3.35, with a volume of 706,226. It is down -0.30% in the last 24 hours and up +15.52% over the past month. X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Previous Close:
$3.36
Open:
$3.33
24h Volume:
706,226
Relative Volume:
0.98
Market Cap:
$332.14M
Revenue:
$9.01M
Net Income/Loss:
-$99.72M
P/E Ratio:
-
EPS:
-$4.54
Net Cash Flow:
-$92.85M
1W Performance:
+3.40%
1M Performance:
+15.52%
6M Performance:
-17.69%
1Y Performance:
-16.04%
1-Day Range:
$3.19$3.41
1-Week Range:
$3.05$3.49
52-Week Range:
$2.43$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
857-529-8300Address
61 NORTH BEACON STREET, BOSTON, MA, USACompare XFOR vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR X 4 Pharmaceuticals Inc | $3.35 | $332.14M | $9.01M | -$99.72M | -$92.85M | -$4.54 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
- David KirskeOct 01 '26Officer
- Transaction
- Proposed Sale
- Cost
- $2.86
- #Shares
- 11,767
- Value ($)
- 33,658
- #Shares Total
- 0
- KIRSKE DAVIDOct 01 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $2.86
- #Shares
- 11,767
- Value ($)
- 33,658
- #Shares Total
- 155,983
- Craig Adam RAug 12 '26Executive Chairman
- Transaction
- Sale
- Cost
- $4.44
- #Shares
- 47,436
- Value ($)
- 210,829
- #Shares Total
- 328,651
- Volpone JohnAug 12 '26President
- Transaction
- Sale
- Cost
- $4.44
- #Shares
- 24,576
- Value ($)
- 109,228
- #Shares Total
- 265,305
- John VolponeAug 12 '26Officer
- Transaction
- Proposed Sale
- Cost
- $4.55
- #Shares
- 24,576
- Value ($)
- 111,944
- #Shares Total
- 0
- Adam CraigAug 12 '26Executive Chaiman
- Transaction
- Proposed Sale
- Cost
- $4.56
- #Shares
- 47,436
- Value ($)
- 216,071
- #Shares Total
- 0
- KIRSKE DAVIDJun 30 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $4.26
- #Shares
- 8,543
- Value ($)
- 36,428
- #Shares Total
- 167,750
- David KirskeMay 12 '26Officer
- Transaction
- Proposed Sale
- Cost
- $4.29
- #Shares
- 16,961
- Value ($)
- 72,820
- #Shares Total
- 0
- KIRSKE DAVIDMay 12 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $4.29
- #Shares
- 16,961
- Value ($)
- 72,820
- #Shares Total
- 176,293
- Craig Adam ROct 23 '25Executive Chairman
- Transaction
- Buy
- Cost
- $2.90
- #Shares
- 86,206
- Value ($)
- 249,997
- #Shares Total
- 376,087
